Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Kan
V L
VL
Nylen
E S
ES
D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D018149:Glucose Intolerance / Q000139:chemically induced* / Q000188:drug therapy; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir / Q000009:adverse effects* / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D018119:Stavudine / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019469:Indinavir; D018119:Stavudine